Carl has extensive experience of designing, implementing and managing Biomarker strategies in human clinical trials across a range of therapeutic areas, including oncology,

respiratory and inflammation, utilising a range of technologies including Flow cytometry, IHC, gene expression profiling, mass spectrometry and ligand binding methodologies.

Carl has experience of biomarkers from both the CRO and Pharma sides of the business as a result of positions held with GSK, Pfizer and Serono amongst others.